AstraZeneca vaccine 79% effective in U.S. trial, panel finds no higher risk of clots

|
PrintFind an error? Report us
AstraZeneca and Oxford University's COVID-19 vaccine was 79% effective in a large U.S. trial at preventing symptomatic illness, and was 100% effective against severe or critical disease and hospitalization, the drugmaker said on Monday.
The fresh data comes after many countries resuming use of the vaccine after the European Medicines Agency (EMA) and the World Health Organization (WHO) said the benefits outweighed the risks following investigations into reports of blood clots.
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
""